Dr Reddy’s

Go Back

Dr Reddy’s

  • Global pharmaceutical company
  • Compound annual growth rate (CAGR) of 14 per cent during FY 09–14
  • Consolidated revenues of Rs 116.3 billion (US$ 1.92 million) in FY 13
  • 18 per cent growth in net profit in FY 13

Dr Reddy’s began as an active pharmaceutical ingredients (API) manufacturer in 1984, producing high-quality APIs for the Indian domestic market. In 1987, the company started its formulations operations and, after becoming a force to reckon with in the Indian formulations market, went international in 1991.

Dr Reddy’s today is more than a 200-million dollar venture with presence in almost all major therapeutic areas. The company is committed to providing affordable and innovative medicines for healthier lives. Through its three businesses – Pharmaceutical Services and Active Ingredients, Global Generics, and Proprietary Products, Dr Reddy’s offers a portfolio of products and services including APIs, custom pharmaceutical services, generics, biosimilars and differentiated formulations. The company’s major therapeutic focus is on gastrointestinal, cardiovascular, diabetology, oncology, pain management and anti-infective. Major markets for Dr Reddy’s include India, USA, Russia-CIS and Europe, apart from other select geographies within emerging markets.

Recently, Dr Reddy’s deepened its focus into the rural markets in India to ensure the expansion of its reach. In this initiative, the company collaborated with its CSR wing, Dr Reddy’s Foundation to reach the millions who are still away from effective treatment and availability of the right medicines.

Source: http://www.drreddys.com

Dr Reddy: Providing affordable and innovative healthcare

2013 Features in ‘Forbes Asia Fab 50 companies’ list at a special Forbes Asia Fab 50 awards ceremony held in China
2011 Receives Pharmexcil Award (Gold Prize) for ‘Outstanding Export Performance for 2010–11’ in the ‘Large Scale Industry’ category
2009 Announces Strategic Alliance with GlaxoSmithKline for emerging markets
2007 Launches Reditux™ (Rituximab) – the world’s first biosimilar of a monoclonal antibody
2005 Acquires Roche’s API business in Mexico

Updated: March, 2014

Pharmaceuticals
India's pharmaceutical sector will touch US$ 45 billion by 2020.
x IBEF : India Brand Equity Foundation